Repligen Corp (RGEN) Stock Price
RGENStock
$175.42+13.50%52W
Market Cap$11.14B
P/E227.79x
PEG Ratio1.78
Div yield—
Beta1.14
RGEN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)23.97%
Price vs S&P 500 (4W)-1.60%
PEG Ratio1.78
VGM Score51.88
P/E Ratio (Annual)227.79x
RGEN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.45 | $0.54 | +20.38%(+$0.09) | |
| Q1 2026 | $0.39 | $0.48 | +22.87%(+$0.09) | |
| Q4 2025 | $0.44 | $0.49 | +10.38%(+$0.05) | |
| Q3 2025 | $0.42 | $0.46 | +10.56%(+$0.04) | |
| Q2 2025 | $0.39 | $0.37 | -5.03%(-$0.02) |
RGEN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.07
4.07
4.11
4.11
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
RGENRepligen Corp | F | C | A | 14.2x | 16.5% | 53.8% | -4.9% | $175.42 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Repligen Corp
Repligen develops and sells bioprocessing equipment and supplies for manufacturing biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. The company serves biopharmaceutical companies and contract manufacturers globally with four core product categories: filtration and fluid management (55% of revenue), chromatography (21%), proteins (11%), and process analytics (13%). Revenue is geographically balanced across North America (44%), Europe (37%), and Asia Pacific (19%).